Close

Anti-EBV Determinant Variant T cell receptor ((CF34)-3), pCDTCR1 (TCR-YC0340)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The recognition of HLA-B8-FLRGRAYGL by two archetypal TCRs was compared. One was a publicly selected TCR, LC13, that is alloreactive with HLA-B44; the other, CF34, lacks HLA-B44 reactivity because it arises when HLA-B44 is coinherited in trans with HLA-B8. Whereas the alloreactive LC13 TCR docked at the C terminus of HLA-B8-FLRGRAYGL, the CF34 TCR docked at the N terminus of HLA-B8-FLRGRAYGL, which coincided with a polymorphic region between HLA-B8 and HLA-B44. The markedly contrasting footprints of the LC13 and CF34 TCRs provided a portrait of how self-tolerance shapes the specificity of TCRs selected into the immune repertoire.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EBV Determinant Variant
  • Target Species
  • EBV
  • Epitope
  • YLRGRAYGL
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-B*08:01
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • CF34
  • Host Species
  • Human

Target

  • Introduction
  • It has been explored the in vivo memory cytotoxic T lymphocyte (CTL) response to an immunodominant HLA-B8-restricted epitope, FLRGRAYGL, from the latent EBV antigen, EBNA 3A. Remarkably, the immune response to HLA-B8-FLRGRAYGL is characterized by type III-biased TCR usage (the reproducible selection of clonal TCR sequences) identifiable in unrelated HLA-B8+ individuals.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-EBV Determinant Variant T cell receptor ((CF34)-3), pCDTCR1 (TCR-YC0340). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.